Bal Pharma Limited (BOM:524824)

India flag India · Delayed Price · Currency is INR
88.84
+1.23 (1.40%)
At close: Jun 18, 2026
Market Cap1.41B -7.8%
Revenue (ttm)3.12B +2.8%
Net Income62.84M -12.9%
EPS3.95 -13.2%
Shares Out 15.92M
PE Ratio22.49
Forward PEn/a
Dividend1.20 (1.37%)
Ex-Dividend DateSep 18, 2025
Volume851
Open87.00
Previous Close87.61
Day's Range87.00 - 90.17
52-Week Range59.69 - 112.97
Beta0.49
Analystsn/a
Price Targetn/a
Earnings DateMay 27, 2026

About Bal Pharma

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic p... [Read more]

Industry Pharmaceutical Preparations
Founded 1987
Employees 986
Stock Exchange Bombay Stock Exchange
Ticker Symbol 524824
Full Company Profile

Financial Performance

In fiscal year 2026, Bal Pharma's revenue was 3.12 billion, an increase of 2.83% compared to the previous year's 3.03 billion. Earnings were 62.84 million, a decrease of -12.91%.

Financial Statements